A tardive dyskinesia drug target VMAT-2 participates in neuronal process elongation

Abstract Tardive dyskinesia involves involuntary movements of body parts and is often observed in individuals taking antipsychotics for extended periods. Initial treatment strategies include reducing medication dosage, switching medications, or using drugs to suppress symptoms. One of the therapeuti...

詳細記述

書誌詳細

出版年:	Scientific Reports
主要な著者:	Miki Ishida, Ryuya Ichikawa, Katsuya Ohbuchi, Hiroaki Oizumi, Yuki Miyamoto, Junji Yamauchi
フォーマット:	論文
言語:	英語
出版事項:	Nature Portfolio 2025-04-01
主題:	Reserpine Tetrabenazine VMAT-2 Tardive dyskinesia CRISPR-Cas13 Elongation
オンライン･アクセス:	https://doi.org/10.1038/s41598-025-97308-5